Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01095848 · ClinicalTrials.gov registry record · Phase 1
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer
A Phase 1 study, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT01095848 is a Phase 1 study that has completed, run by ImmunoVaccine Technologies, Inc. (IMV Inc.). The registered enrollment target is 23 participants.
The verdict
NCT01095848, a Phase 1 study, has completed, sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
To determine the safety and immunogenicity profile of two (2) different doses of the vaccine DPX-0907 to treat breast, ovarian and prostate cancer.
Interventions
- BIOLOGICAL DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2010-03 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01095848
The ClinicalTrials.gov registry entry for NCT01095848 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoVaccine Technologies, Inc. (IMV Inc.), which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG is the first listed.
NCT01095848 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01095848 about?
NCT01095848 is a clinical study titled "A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer". To determine the safety and immunogenicity profile of two (2) different doses of the vaccine DPX-0907 to treat breast, ovarian and prostate cancer.
What is the current status of trial NCT01095848?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2010-03. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01095848?
The interventions under investigation include: DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG (BIOLOGICAL).
Who is sponsoring clinical trial NCT01095848?
This trial is sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.), which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.